Business Wire

INTERSOLAR EUROPE 2022: FOCUS ON INTELLIGENT DUAL USE OF AREAS

Share

At the Intersolar Europe exhibition, established and new players in the energy sector exchange information about new developments and trends, experience innovations and exploit business potential. The focus of the world’s leading exhibition for the solar industry is, among other things, the dual use of areas in agriculture, on bodies of water and in buildings. Intersolar Europe will be held at Messe München from May 11 to 13.

Photovoltaic (PV) production is booming in Germany and throughout Europe: almost 26 gigawatts (GW) of PV installations were connected to the grid in the EU in 2021 – a record growth of 34%. As in the previous year, Germany was the largest PV market in the EU with an addition of 5.3 GW. The European inter-trade organization, SolarPower Europe, expects installed solar power capacity to double to more than 326 GW by 2025.

At Intersolar Europe 2022, companies will present innovations and products developed for the world of new energies. Some examples include Agri-photovoltaics and Floating PV. The efficient dual use of areas for agriculture and solar power generation is developing dynamically: in 2020, plants for the generation of more than 14 GW had already been installed worldwide, according to the Fraunhofer Institute for Solar Energy Systems (ISE). Floating PV is now considered the third pillar of the global solar market. An estimated 400 plants with a total capacity of more than 3 GW are already in operation in over 40 countries. At Intersolar Europe 2022, these rapid developments will be prominent, with a large number of exhibitors presenting innovative products and solutions from the Agri-PV and Floating PV sectors.

Building-integrated PV (BIPV) is another key topic at Intersolar Europe 2022. With a view to the German market, this is where the greatest potential can be found for reducing the CO2 footprint of buildings, using space efficiently and strengthening sustainable development.

Intersolar Europe forms part of The smarter E Europe. From May 11 to 13, 2022, it will present cross-industry and cross-sector solutions for the energy transition and security of supply in Europe at Messe München. 1,450 exhibitors will showcase products, solutions and business models across 132,000 square meters in twelve exhibition halls.

Topics such as Agri-PV, Floating PV and BIPV will also be addressed at the Intersolar Europe Conference on May 10 and 11, 2022 at the International Congress Center Munich (ICM). Participants will learn all about the markets, technologies and financing of PV projects. One area under the spotlight will be large-scale PV power plants and systems, especially with regard to Agri-PV and floating PV. On May 10 at 6 p.m., innovators and experts will be honored with the Intersolar AWARD at the ICM (Hall 1).

https://www.intersolar.de/home?lang=en

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Solar Promotion GmbH | PO Box 100 170 | 75101 Pforzheim
Horst Dufner | +49 7231 58598-0
info@intersolar.de

Press-contact:
fischerAppelt, relations | Otl-Aicher-Str. 64 | 80807 Munich
Felizia Rein | +49 89 74 74 66 40
felizia.rein@fischerappelt.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye